TheraRadar
← Back
Data updated: Jul 17, 2026

BIONPHARMA

Generics
NeurologyImmunologyInfectious Disease

BIONPHARMA is a generic drug manufacturer focused on Neurology, Immunology, Infectious Disease.

1974
Since
73
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

BIONPHARMA's Key Drugs

BIONPHARMA's core commercial portfolio centers on SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, ACETAMINOPHEN AND IBUPROFEN, spanning Neurology and Immunology — its most strategically important drugs approved in the last 15 years.

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE
Gastrointestinal
Approved 2017
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Pain
Approved 2014
ACETAMINOPHEN AND IBUPROFEN
Pain
Approved 2023

BIONPHARMA's Recent FDA Approvals

BIONPHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

BIONPHARMA's Therapeutic Areas

BIONPHARMA's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 41%
7 drugs
Immunology 18%
3 drugs
Infectious Disease 18%
3 drugs
Cardiovascular 12%
2 drugs
Respiratory 12%
2 drugs

BIONPHARMA Pipeline Snapshot

Active clinical trials for BIONPHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Neurology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling